Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000, C544S231000, C540S559000, C540S555000, C514S267000
Reexamination Certificate
active
06943171
ABSTRACT:
A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:
REFERENCES:
patent: 5250534 (1993-10-01), Bell et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5346901 (1994-09-01), Bell et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5409934 (1995-04-01), Smith et al.
patent: 5470579 (1995-11-01), Bonte et al.
patent: 5688768 (1997-11-01), Coughlin et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5759994 (1998-06-01), Coughlin et al.
patent: 5798248 (1998-08-01), Coughlin et al.
patent: 5824683 (1998-10-01), McKittrick et al.
patent: 5856448 (1999-01-01), Coughlin
patent: 5859006 (1999-01-01), Daugan
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5877216 (1999-03-01), Place et al.
patent: 5939419 (1999-08-01), Tulshian et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 5981527 (1999-11-01), Daugan et al.
patent: 6024936 (2000-02-01), Coughlin et al.
patent: 6025494 (2000-02-01), Daugan
patent: 6037346 (2000-03-01), Doherty, Jr. et al.
patent: 6100270 (2000-08-01), Campbell
patent: 6124101 (2000-09-01), Coughlin
patent: 6140329 (2000-10-01), Daugan
patent: 6143746 (2000-11-01), Daugan et al.
patent: 6197541 (2001-03-01), Coughlin
patent: 6362178 (2002-03-01), Niewöhner et al.
patent: 6403597 (2002-06-01), Wilson et al.
patent: 6469012 (2002-10-01), Ellis et al.
patent: 6469016 (2002-10-01), Place et al.
patent: 6472434 (2002-10-01), Place et al.
patent: 6512002 (2003-01-01), Lee et al.
patent: 2003/0153587 (2003-08-01), Asberom et al.
patent: 0 389 282 (1990-09-01), None
patent: 0 526 004 (1992-07-01), None
patent: 0 463 756 (1995-04-01), None
patent: 0 702 555 (1996-03-01), None
patent: 2 116 302 (1972-07-01), None
patent: 89/10123 (1989-11-01), None
patent: 91/19717 (1991-12-01), None
patent: WO 91/19717 (1991-12-01), None
patent: 92/05175 (1992-04-01), None
patent: 92/05176 (1992-04-01), None
patent: 93/23401 (1993-11-01), None
patent: 94/19351 (1994-09-01), None
patent: WO 94/19351 (1994-09-01), None
patent: 94/28902 (1994-12-01), None
patent: 96/16644 (1996-06-01), None
patent: 96/16657 (1996-06-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/03985 (1997-02-01), None
patent: 97/24334 (1997-07-01), None
patent: 97/43287 (1997-11-01), None
patent: 98/08848 (1998-03-01), None
patent: 98/15530 (1998-04-01), None
patent: 98/38168 (1998-09-01), None
patent: 98/49166 (1998-11-01), None
patent: 99/00359 (1999-01-01), None
patent: 99/00373 (1999-01-01), None
patent: 99/21558 (1999-05-01), None
patent: 99/21831 (1999-05-01), None
patent: 99/24433 (1999-05-01), None
patent: 99/42452 (1999-08-01), None
patent: 99/43674 (1999-09-01), None
patent: 99/43679 (1999-09-01), None
patent: 99/54333 (1999-10-01), None
patent: 99/62905 (1999-12-01), None
Suzuki, Chem Pharm Bull 50(9) 1163 (2002).
U.S. Appl. No. 60/383,478, filed May 31, 2002, Dahanukar.
U.S. Appl. No. 60/384,484, filed May 31, 2002, Dahanukar.
U.S. Appl. No. 09/940,760, filed Aug. 28, 2001, Chackalamannil.
U.S. Appl. No. 10/227,778, filed Aug. 26, 2002, Asberom.
Ho-Sam Ahn et al, “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”,J. Med. Chem.,vol. 40, No. 14, pp. 2196-2210 (1997).
Kent S. Allenby et al, “Pentoxifylline in the Treatment of Vascular Impotence—Case Reports”, pp. 418-420 (1991).
J.L. Ambrus et al, “Studies on Vasoocclusive Crisis of Sickle Cell Disease. I. Effect of Pentoxifylline”,Journal of Medicine, vol. 10, No. 6, pp. 445-456 (1979).
Bradley D. Anderson et al, “Preparation of Water-Soluble Compounds Through Salt Formation”, The Practice of Medicinal Chemistry, C. G. Wermuth, Ed.,Academic Press,New York, pp. 739-754 (1996).
M.I. Argel et al, “Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein Kinase Activity and Cyclic Nucleotide Levels”,J. Mol. Cell Cardiol,vol. 12, No. 10, pp. 939-954, Abstract (1980).
Hans-Joachim Arnold et al, “Pharmacopoeia of Traditional Medicine in Venda”,Journal of Ethnopharmacology,vol. 12, pp. 35-74 (1984).
William J. Aronson et al,“The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide”,The Journal of Urology,vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).
Joseph A. Beavo, “Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms”,Physiological Reviews,vol. 75, No. 5, pp. 725-748 (Oct. 1995).
Joseph A. Beavo & David H. Reifsnyder, “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors”,Trends in Pharmacological Sciences,vol. 11, No. 4, pp. 150-155 (Apr. 1990).
Stephen M. Berge et al, “Pharmaceutical Salts”, J. ofPharmaceutical Sciences,Am. Pharm Assoc. and Pergamon Press, vol. 66, No. 1, pp. 1-19 (Jan. 1977).
Anne Bowman et al, “Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle”,Br. J. Pharmac.,vol. 81, pp. 665-674 (1984).
V. Mirone et al, letter to ed. re. “Intracavernous Cyclic GMP Products Produces Penile Erection in Patients with Erectile Dysfunction”,British Journal of Urology,vol. 71, No. 3, p. 365 (Mar. 1993).
Gary Brooker et al, “Radioimmunoassay of Cyclic AMP and Cyclic GMP”,Advances in Cyclic Nucleotide Research,Paul Greengard et al, Eds., vol. 10, pp. 1-33 (1979).
Margaret Ann Bush, “The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of corpus cavernosum smooth muscle”, Ph.D. dissertation U.C.L.A. (UMI Dissertation Services Order No. 9319914) (179 pgs) (1993).
Peggy Bush et al, “Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum”,Journal of Urology,vol. 147, pp. 1650-1655 (Jun. 1992).
S. Carrier et al, “Erectile Dysfunction,”Endocrinology and Metabolism Clinics of North America: Clinical Andrology,vol. 23, No. 4, pp. 773-782 (Dec. 1994).
P. Cazzulani et al, “Pharmacological Activities of the Main Metabolite of Flavoxate 3-Methylflavone-8-carboxylic Acid”,Drug Res.,vol. 38 (I), No. 3, pp. 379-382 (1988).
J. Cortijo et al, “Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including Studies with Human Bronchus”,Br. J. Pharmacol.,vol. 108, pp. 562-568 (1993).
Jacob de Boer et al, “Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors”,Br. J. Pharmacol.,vol. 106, pp. 1028-1034 (1992).
Dario Doller et al, “The GIF System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG III Conditions”,Bioorganic and Medicinal Chemistry Letters,vol. 7, No. 11, pp. 1381-1386 (1997).
I.J. Fishman, “Treating Erectile Dysfunction: New Approaches”,Drug Therapy,vol. 8, pp. 102-110 (Aug. 1989).
P.G. Gillespie & J.A. Beavo, “Inhibition and Stimulation of Photoreceptor Phosphodiesterases by Dipyridamole and M & B 22,948”,Molecular Pharmacology,vol. 36, pp. 773-781 (Nov. 1988).
J.C. Gingell, et al, “Emerging pharmacological therapies for erectile dysfunction”,Exp. Opin. Ther. Patents,vol. 9, No. 12, pp. 1689-1696 (1999).
Philip L. Gould, “Salt Selection for Basic Drugs”,Int'l J. of Pharmaceutics,Elsevier, vol. 33, pp. 201-217 (1986).
Theodora W. Greene, “Protective Groups in Organic Synthesis”, John Wiley & Sons, Inc., New York, pp. 1-9 (1981).
Alain Gregoire, “Viagra: on release”,BMJ,vol. 317, p. 759-760 (Sep. 19, 1998).
“Pharmaceutical Coloring Agents”, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1986).
Takeru Higuchi, “Prodrug & Drug Delivery—An
Asberom Theodros
Clader John W.
Hu Yueqing
Pissarnitski Dmitri A.
Stamford Andrew W.
Berch Mark L.
Reinhardt Gerard E.
Schering Corporation
LandOfFree
Polycyclic guanine derivative phosphodiesterase V inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polycyclic guanine derivative phosphodiesterase V inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polycyclic guanine derivative phosphodiesterase V inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405003